BMY is banking on new drugs to offset generic competition for older drugs. However, this might not be enough as the outlook ...

The EC approves BMY's combination of Opdivo and Yervoy for the first-line treatment of adult patients with unresectable or ...

An oncologist from Atrium Health outlines how saving time administering immunotherapy could have far-reaching benefits.

Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma ...

Bristol-Myers Squibb Company (NYSE:BMY) 45th Annual TD Cowen Health Care Conference March 4, 2025 2:30 PM ETCompany ParticipantsAdam Lenkowsky - ...

The recent approval of Opdivo Qvantig, a subcutaneous formulation of the company’s PD-1 inhibitor, is expected to change market share dynamics in the competitive oncology space due to its easier and ...

The recent approval of Opdivo Qvantig, a subcutaneous formulation of the company's PD-1 inhibitor, is expected to change market share dynamics in the competitive oncology space due to its easier ...

BMS’ Opdivo is approved in more than 65 countries. Credit: Amy Lutz/Shutterstock. The US Food and Drug Administration (FDA) has accepted Bristol Myers Squibb’s (BMS) supplemental biologics licence ...

The recent approval of Opdivo Qvantig (a cancer drug) in 2024 demonstrates the company's R&D capabilities, while its strong cash position of 11 billion dollars provides ample resources for ...